This App Can Help Track Multiple Sclerosis

Roche looked into how the patients interacted with FLOODLIGHT and found that they were "highly engaged" with the mobile assessments. When analyzing those who had been a part of the program for at least 14 weeks, almost eighty percent of patients who had multiple sclerosis abided by the active tests and around ninety percent complied with the method of monitoring utilized by the app. Healthy controls outnumbered each of these statistics.

Roche took these results to believe that FLOODLIGHT is certainly capable of what they set out for it to do - empower patients. The clinical trial data does indeed support these claims, and has offered an entirely new method into the tracking of multiple sclerosis.